Official Title
Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial
Brief Summary

The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over 20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. The current preventative strategies are non-specific10, and current interventions are predominantly supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.

Unknown status
COVID-19 Acute Respiratory Distress Syndrome

Drug: Lidocaine

Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs

Eligibility Criteria

Inclusion Criteria:

- Covid-19 positive

- Moderate to severe ARDS

Exclusion Criteria:

- patients with COPD or taking bronchodilators and steroids for chronic respiratory
illnesses

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 70 Years
Countries
Pakistan
Locations

Sheikh zayed medical college & hospital
Rahim Yar Khan, Punjab, Pakistan

Investigator: alina a umar, MCPS
Contact: 0092 689230165
alinaumar1@gmail.com

Contacts

sairah s sadaf, FCPS
0092 689230165 - 245
sairahbabar@live.com

Sheikh Zayed Medical College
NCT Number
MeSH Terms
COVID-19
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Lidocaine